a-chain

Telimomab aritox (T101-ricin A chain immunotoxin) is a mouse monoclonal antibody fused to the A chain of ricin protein, functioning as an immunosuppressive agent [1].

Dorlimomab aritox (4197X-RA; MDX-RA [ricin A chain] immunotoxin) is a monoclonal antibody of mouse origin that is conjugated to the A chain of ricin [1].

Grisnilimab setaritox (WT1-RTA), an anti-CD7 antihuman T cell antibody linked to ricin A chain (RTA), exhibits in vitro cytotoxicity against CEM (T-lymphoblastic leukemia) cells with an ID 50 of 53 pM. The 30-kDa RTA component disrupts the function of 60S ribosomal subunits. Additionally, Grisnilimab setaritox has demonstrated efficacy in ameliorating leukemic meningitis in a rhesus monkey model [1].

Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment exhibiting low picomolar affinity (K D = 1.05 pM), utilized for cancer research [1] [2].

Osemitamab, an IgG1 antibody, targets human claudin-18.2 and comprises a human-Mus musculus monoclonal TST001 γ1-chain disulfide-bonded to a human-Mus musculus monoclonal TST001 κ-chain dimer (ACI). It is utilized, in conjunction with Capecitabine and Oxaliplatin, for gastric/gastroesophageal junction (G/GEJ) cancer studies [1] [2].

Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody with affinity for the beta chain of the OSM receptor and inhibition of IL-31 and OSM signaling.Vixarelimab can be used to study severe nodular itch and idiopathic pulmonary fibrosis.

Ordesekimab (AMG 714) is a human IgG1 κ-anti-IL-15 (Interleukin Related) monoclonal antibody. Ordesekimab binds competitively to IL-15, inhibiting the interaction of IL-15 with the common gamma chain of the IL-2Rβ and IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab can be used to study non-reactive celiac disease (NRCD).

Catumaxomab, a trifunctional IgG2 antibody with mouse and rat heavy and light chain components, targets human EpCAM and CD3 receptors. Its Fc region exhibits affinity for FcγRI (CD64), FcγRIIA (CD32a), and FcγRIII (CD16), making it a valuable tool in epithelial cancer anti-tumor research [1] [2].

Enoticumab (REGN421, SAR153192) is an IgG1κ antibody that specifically targets human Delta-like ligand 4 (Dll4), which serves as a crucial component of the Notch signaling pathway and regulates the uptake of fatty acids through non-transcriptional modulation of macropinocytosis-dependent long-chain fatty acid absorption. Demonstrated efficacy in vivo, Enoticumab was shown to inhibit tumor growth by 86% and 83% in subcutaneous TOV-112D and intraperitoneal A2780 human ovarian tumor xenograft mouse models, respectively, when administered at a dose of 2.5 mg/kg weekly [1].

Birtamimab (NEOD001) is a monoclonal antibody under investigation for its ability to selectively target and eliminate amyloid in the treatment of light chain amyloidosis [1].

Apolizumab (Hu1D10), a humanized monoclonal antibody targeting the Human leukocyte antigen-DR beta-chain, has been shown to induce apoptosis in chronic lymphocytic leukemia (CLL) cells in vitro [1] [2].

Iparomlimab, an IgG4κ anti-human PD-1/CD279/PDCD1 antibody, additionally binds to the human monoclonal PSB103 γ4-chain, forming a dimer through disulfide linkage with the human monoclonal PSB103 κ-chain. It is utilized in oncology research [1].

Licaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment that targets TNF alpha, an inflammatory cytokine produced by macrophages and monocytes during inflammation [1].